Barts Cancer Institute

Running trials

• Recruiting

  Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

  NCT06954480· Phase 2· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

  NCT05840211· Phase 3· Source

• Active, not recruiting

  PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

  NCT04360941· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

  NCT06525675· Source

• Completed

  A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)

  NCT04907851· Phase 2· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

  NCT03036488· Phase 3· Source

• Completed

  A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT02500407· Phase 1/2· Source

Trial sites

• Barts Cancer Institute4 trials
• Barts Cancer Institute, Centre of Experimental Cancer Medicine1 trial
• Barts Cancer Institute - Haemato-Oncology1 trial
• Barts Cancer Institute (Site 1500)1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Bladder cancer39 works · 0 trials
• Kidney cancer36 works · 0 trials
• Triple-negative breast cancer24 works · 3 trials
• Metastatic breast cancer15 works · 4 trials